Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis To demonstrate the superiority of secukinumab 150 mg and/or 300 mg to placebo in subjects with moderate to severe palmoplantar psoriasis as assessed by the palmoplantar Investigator's Global Assessm...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Clofazimine treatment of multidrug-resistant tuberculosis (MDRTB) The primary objective is to evaluate the effect of clofazimine added to BR over BR alone in producing higher cure rates at Month 30 post-randomization based on liquid culture media results in Mycobact...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An open-label extension study of CACZ885H2357E1 on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/ or colchicine are contraindicated, not tolerated or ineffective The primary objective of this study is to confirm the long-term safety and tolerability of canakinumab 150 mg s.c.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A multi-center, double-blind, placebo-controlled, proof-of-concept study to evaluate the efficacy and tolerability of KRP203 in patients with active subacute cutaneous lupus erythematosus To assess the preliminary clinical efficacy of oral KRP203 in clinically active, treatment refractory patients with subacute cutaneous lupus erythematosus (SCLE) after 12 weeks of treatment with KPR20...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A randomized, double-blind, two way cross-over, proof of concept study to compare the efficacy, safety, pharmacokinetics and pharmacodynamics of two-week oral administration of QAV680 versus placebo, with an extended open-label inhaled corticosteroid period, in steroid-free, mild to moderate persistent asthma patients • To assess the efficacy and safety of multiple doses of QAV680 (500 mg BID over 14 days) compared to placebo in mild to moderate persistent steroid free asthma patients

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study of application of Power Doppler ultrasonography (PDUS) to measure response to secukinumab treatment in patients with active psoriatic arthritis (PsA) To demonstrate that there is a difference between secukinumab and placebo in terms of joint synovitis response over 12 weeks as measured by the PDUS Global OMERACT-EULAR Synovitis Score (GLOESS) of th...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An eight-week double-blind, multi-center, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren 75mg, 150mg and 300mg in elderly patients with essential hypertension when given with a light meal Confirm the efficacy of aliskiren 75 mg, 150 mg and 300 mg in elderly patients with essential hypertension when given with a light meal by testing the hypothesis of superior reduction in mean sitting ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A randomized, double-blind, cross-over, 4-period, 4 treatment, within-subject placebo-controlled study to assess the optimal renoprotective dose of Aliskiren in hypertensive type 2 diabetes patients with incipient or overt nephropathy • Investigate the antiproteinuric effect of increasing dose administration of Aliskiren versus Aliskiren matching placebo

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A 13-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel group trial of lumiracoxib (COX189) 100 mg o.d. in patients with primary hip osteoarthritis using celecoxib (200 mg o.d.) as a positive control To demonstrate the efficacy of lumiracoxib in primary hip osteoarthritis by testing the hypotheses that lumiracoxib 100 mg o.d. is superior to placebo with respect to the pain sub-scale of the WOMAC 3...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An open-label study to investigate blood concentrations, safety, tolerability and efficacy of Elidel® Cream 1% in patients with moderate or severe seborrheic dermatitis treated topically for 3 weeks •To measure the blood concentrations of pimecrolimus after single and repeated doses of Elidel (pimecrolimus) Cream 1% when applied twice daily for 3 weeks on the whole lesional skin in patients with ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune